DR.MAAMON AMEEN
Introduction
 NPC is a squamous-cell carcinoma arising from epithelial lining of the
nasopharynx.
 Most common malignancy in the nasopharynx
 Nasopharyngeal malignancies
 SCCA (nasopharyngeal carcinoma)
 Lymphoma
 Salivary gland tumors
 Sarcomas
Race: More in Chinese & North African people
Sex: Male preponderance of 3:1
Age: -Its incidence rate starts to rise after the second decade of life.
-Median age is 50 years .
Gross: Proliferative, Ulcerative & Infiltrative types
The most common location is Fossa of Rosenmuller
Introduction
Anatomy
Lymphatic drainage
 Lateral Retropharyngeal L.N also called as
nodes of Röuviere, are the first nodes in the
lymphatic drainage of Nasopharynx.
 Extends from base of skull to C3 cervical
vertebra.
Endoscopic anatomy
Radiological anatomy
GENETIC
ENVIORMENT
VIRAL
Etiology
Etiology
Genetic:
 Commonest in Chinese population.
 Genomic studies have revealed 3 HLA locus.
 HLAA2; HLA B46; HLA B17 are associated with increased risk of NPC
Viruses:
 EBV- well documented viral “fingerprints” in tumor cells and also anti-
EBV serologies with WHO type II and III NPC
 HPV - possible factor in WHO type I lesions
Etiology
Environmental:
 salted fish food contain nitrosamines: carcinogen
 Lack of vit C in diet
 Burning of incense & woods: polyaromatic hydrocarbon:carcinogen
 Alcohol consumption & Cigarette smoking
 occupational exposure to dust, smoke, and chemical fumes
W.H.O. classification of NPC
 1- keratinizing squamous cell ( 25% )
 2. Type II is non-keratinizing squamous carcinomas 12 %
 3. Type III is the undifferentiated carcinomas 60 %
Clinical Features
Upper neck swelling 50%
Clinical Features
Nasal symptoms 30%
 Blood-stained post-nasal discharge
 progressive nasal obstruction,
 Epistaxis
Clinical Features
Otological symptoms:
 Hearing loss
 Otalgia
 Otorrhoea
 Tinnitus
Clinical Features
Ophthalmologic symptoms :
 Diplopia & ophthalmo-plegia (involvement of CN III, IV, VI),
 Proptosis (orbit invasion) &
 Blindness (involvement of CN II).
Clinical Features
Neurologic (25-40 %):
Headache: indicates skull base erosion
Facial pain - Trigeminal
Xerophthalmia - greater sup. petrosal n
Jugular foramen syndrome: CN IX, X, XI involved by lateral retropharyngeal lymph
node
Clinical Features
Other symptoms
 Weight loss
 Anorexia
 Trismus
 Distant metastasis: to bone, lung & liver
Clinical Features
Diagnostic Evaluation
High index of suspicion required for early diagnosis
• Clinical evaluation
• Radiological evaluation
• Laboratory evaluation
• Histopathological evaluation
Diagnostic Evaluation
Clinical evaluation
 Detailed medical history
 Examination :
 General physical examination
 Complete head and neck examination
Diagnostic Evaluation
Clinical examination of nasophyrnx:
Indirect nasophayrngoscopy with mirror
Direct nasopharyngoscopy with fiber-optic scope
Rigid 0 and 30* Hopkins rod endoscope
Diagnostic Evaluation
Diagnostic Evaluation
Diagnostic Evaluation
Radiological Evaluation
 Help to make the correct diagnosis
 Help To know the disease stage
 Help to determine the target volume of radiotherapy
 Help to evaluate the treatment results
 Follow-up
Diagnostic Evaluation
 CT Scan
 Extent of tumor
 Neck node involvement
 Skull base erosion
 MRI – radiologic modality of choice
 Determine if any intracranial extension of the tumour involves the brain
parenchyma or the cavernous sinus
 MRI > CT for displaying both superficial and deep nasopharyngeal soft tissue
and for differentiating tumor from soft tissue.
Diagnostic Evaluation
Diagnostic Evaluation
Diagnostic Evaluation
Diagnostic Evaluation
 Positron emission tomography (PET) :
- Useful in diagnosing recurrent /residual lesion following RT.
-Useful to exclude distant metastasis before major salvage .
 Chest x-ray:
To identify lung metastasis
 Abdominal ultrasound:
To find liver metastasis.
 Bone scan.
Diagnostic Evaluation
Diagnostic Evaluation
Diagnostic Evaluation
Laboratory evaluation
 CBC,
 LFT’s
 Special diagnostic tests (for types II & III)
 IgA antibodies for viral capsid antigen (VCA)
 IgG antibodies for early antigen (EA)
 Antibody Dependent Cellular Cytotoxicity assay.
Diagnostic Evaluation
 Biopsy : first necessary investigation for NPC
 Endoscopic biopsy : Ideally it shuold be carried out
during the patient’s ist outpatient visit in suspected
cases.
 The most common sites are roof of nasopharynx and
fossae of Rosenmuller.
 FNA biopsy : should be done in suspicious neck
lump.
Histopathological Evaluation
T.N.M. staging
T1 = Tumour confined to the nasopharynx or extends to oropharynx and/or nasal cavity
T2 = Tumour with parapharyngeal extension
T3 = invasion of bony structures or P.N.S.
T4 = intracranial, involvement of orbit, cranial nerves, infratemporal fossa,
hypopharynx
T.N.M. staging
N0 = no evidence of regional lymph nodes
N1 = unilateral N2 = bilateral
(Both are above supraclavicular fossa & < 6 cm)
N3 = > 6 cm or in supraclavicular foss
N3a- greater than 6 cm in dimension
N3b- extension to the supraclavicular fossa
M0 = no evidence of distant metastasis
M1 = distant metastasis present
T.N.M. staging
 Stage I = T1 N0 M0
 Stage II = T2 or N1 M0
 Stage III = T3 or N2 M0
 Stage IV = T4 or N3 or M1
NPC
Treatment
 The management of NPC is unique for two reasons:
1-Tumor is in a relatively inaccessible location
2-Tumors is extremely radiosensitive
Treatment
Treatment Modalities
 Radiotherapy (modality of choice)
 Chemotherapy : combination with radiotherapy in advance
disease
 Surgery :To salvage local and regional failure
Radiotherapy
Modes of radiotherapy
 Teletherapy or External beam radiotherapy :Radiation beams projected to the
target area through skin
 Brachytherapy :uses radioactive material which are placed in close contact with
tumor tissue .
Interstitial: Radioactive source inserted into tumor tissue
Intracavitary: Radioactive source placed inside catheter or moulds & inserted into
nasopharynx
Radiotherapy
Modes of radiotherapy
 Intensity modulated radiation therapy (IMRT): recent development in
delivery of radiotherapy where maximum dose can be delivered to the tumor but
saving important normal structure
 Stereotactic radiosurgery
delivers radiation therapy precisely to the tumor using a machine called a gamma
knife. This can be used to treat tumors that have invaded the base of the skull, or
tumors that have recurred at the base of the brain or skull.
primary treatment
Radiotherapy
 External beam radiotherapy is most commonly delivered by opposed lateral fields
to encompass the primary tumor and upper neck
 Treatment field has to cover nasopharynx ,paraphryngeal space ,oropharynx
,skull base,sphenoid sinus ,posterior ethmoid ,posterior half of maxillary sinus
 Bilateral Cervical nodal irradiation is mandatory even in clinically node-negative
patients
primary treatment
primary treatment
 Radiotherapy
 65-70 GY for primary
 65-70 GY for positive L.N
 50-60 GY for negative L.N
 It should be delivered single fraction daily ,five per week without interruption .
 Proper shielding of all critical structures as well as surrounding normal tissue is
important.
primary treatment
Radiotherapy
 Radiation boosts in the form of intracavitary brachytherapy for T1 to T2 lesions
have been used to improve local control rates
 Stereotactic radiosurgery boosts may also be given for T3 and T4 lesions.
primary treatment
Chemotherapy
 Chemotherapy is believed to act as radiosensitizer.
 It helps to reduce the chance of distant metastasis.
 For locally advanced disease (stage III-IV ) chemotherapy in addition to
radiotherapy appears to improve overall results.
 Combination chemotherapy produces better responses
 combination cisplatin/5-flurouracil is the most widely used
 Indicates that concurrent chemoradiotherapy has a major role in advanced stage
NPC
primary treatment
Complications chemotharpy
 Bone marrow suppression
 Sensorineural hearing loss
 Renal impairment
 Hair loss
 Weight loss
 Nausea and vomiting
primary treatment
FOLLOW-UP PLAN:
 Close monitoring of the progress during and after treatment is necessary .
 Follow-up endoscopy at 6–8 weeks and imaging at 10–12 weeks after
completion of radiotherapy or chemoradiotherapy is recommended to document
tumour responses.
 malignancy detected after 10 weeks usually represents viable tumour and salvage
treatment is indicated
primary treatment
FOLLOW-UP PLAN:
 Close monitoring of the progress during and after treatment is necessary .
 The majority of relapses occur in first three years .
 After primary treatment, patient should be seen :
 Two-monthly for the first year
 Three –monthly for 2nd and third year
 Six –monthly thereafter.
 Lifelong follow-up is needed as very late recurrence may also occur
primary treatment
 FOLLOW-UP PLAN:
 The response of local disease is best followed up by repeated nasoendoscopy .
 Post-treatment biopsy indicated if there is any residual swelling at the primary
site .
 Imaging is often needed to evaluate regional disease .
Salvage treatment
Treatment of recurrence
 Recurrence at the primary site can be treated by surgery or re-irradiation.
 Further dose of ERT may be considered.
 Brachytherapy is preferred.
 Cervical nodal recurrences are best treated by surgery .
Salvage treatment
surgery
• Due to deep location of nasopharynx, and anatomic proximity to critical
structures, radical surgery is typically not used
• Limited to
 biopsy
 Neck dissections for persistently enlarged lymph nodes
 Nasopharyngectomy in persistent or recurrent disease
Salvage treatment
Nasopharyngectmy
 Surgical approaches to the nasopharynx:
 Anterior approaches
 Inferior approaches
 Lateral approaches
Salvage treatment
Anterior approaches :
 Lateral rhinotomy
 Transnasl transmaxillary
 Midfacial degloving
 Maxillary swing (most common approach )
Salvage treatment
Inferior approaches :
 Transplatal :For localized tumour in
the lower part of the posterior wall of the nasopharynx
 Mandibular swing
 lateral infratemporal fossa approach: When the main tumour
bulk is located in the paranasopharyngeal space close or
lateral to internal carotid artery
Salvage treatment
 Surgical salvage for neck disease:
 If a neck node persists in the absence of distant metastasis
,radical neck disection (RND)should be performed
Prognosis
 Approximate 5 years survival rates for NPC
Prognostic factors
 TNM
 EBV
 pathologic type
 Old age
 Cranial nerve palsy
 Level and Fixity of nodes

Complications of Radiotherapy
 xerostomia
 Oropharyngeal mucositis
 Alopecia
 Otitis media with effusion(OME)
 Otitis externa
 Rhinosinusitis
 Trismus
 Neck stiffness
 Dysphagia
 sensorineural deafness
npc-170324145154.pdf

npc-170324145154.pdf

  • 1.
  • 2.
    Introduction  NPC isa squamous-cell carcinoma arising from epithelial lining of the nasopharynx.  Most common malignancy in the nasopharynx  Nasopharyngeal malignancies  SCCA (nasopharyngeal carcinoma)  Lymphoma  Salivary gland tumors  Sarcomas
  • 3.
    Race: More inChinese & North African people Sex: Male preponderance of 3:1 Age: -Its incidence rate starts to rise after the second decade of life. -Median age is 50 years . Gross: Proliferative, Ulcerative & Infiltrative types The most common location is Fossa of Rosenmuller Introduction
  • 4.
  • 8.
    Lymphatic drainage  LateralRetropharyngeal L.N also called as nodes of Röuviere, are the first nodes in the lymphatic drainage of Nasopharynx.  Extends from base of skull to C3 cervical vertebra.
  • 9.
  • 10.
  • 11.
  • 12.
    Etiology Genetic:  Commonest inChinese population.  Genomic studies have revealed 3 HLA locus.  HLAA2; HLA B46; HLA B17 are associated with increased risk of NPC Viruses:  EBV- well documented viral “fingerprints” in tumor cells and also anti- EBV serologies with WHO type II and III NPC  HPV - possible factor in WHO type I lesions
  • 13.
    Etiology Environmental:  salted fishfood contain nitrosamines: carcinogen  Lack of vit C in diet  Burning of incense & woods: polyaromatic hydrocarbon:carcinogen  Alcohol consumption & Cigarette smoking  occupational exposure to dust, smoke, and chemical fumes
  • 14.
    W.H.O. classification ofNPC  1- keratinizing squamous cell ( 25% )  2. Type II is non-keratinizing squamous carcinomas 12 %  3. Type III is the undifferentiated carcinomas 60 %
  • 15.
  • 16.
    Clinical Features Nasal symptoms30%  Blood-stained post-nasal discharge  progressive nasal obstruction,  Epistaxis
  • 17.
    Clinical Features Otological symptoms: Hearing loss  Otalgia  Otorrhoea  Tinnitus
  • 18.
    Clinical Features Ophthalmologic symptoms:  Diplopia & ophthalmo-plegia (involvement of CN III, IV, VI),  Proptosis (orbit invasion) &  Blindness (involvement of CN II).
  • 19.
    Clinical Features Neurologic (25-40%): Headache: indicates skull base erosion Facial pain - Trigeminal Xerophthalmia - greater sup. petrosal n Jugular foramen syndrome: CN IX, X, XI involved by lateral retropharyngeal lymph node
  • 20.
    Clinical Features Other symptoms Weight loss  Anorexia  Trismus  Distant metastasis: to bone, lung & liver
  • 21.
  • 22.
    Diagnostic Evaluation High indexof suspicion required for early diagnosis • Clinical evaluation • Radiological evaluation • Laboratory evaluation • Histopathological evaluation
  • 23.
    Diagnostic Evaluation Clinical evaluation Detailed medical history  Examination :  General physical examination  Complete head and neck examination
  • 24.
    Diagnostic Evaluation Clinical examinationof nasophyrnx: Indirect nasophayrngoscopy with mirror Direct nasopharyngoscopy with fiber-optic scope Rigid 0 and 30* Hopkins rod endoscope
  • 25.
  • 26.
  • 27.
    Diagnostic Evaluation Radiological Evaluation Help to make the correct diagnosis  Help To know the disease stage  Help to determine the target volume of radiotherapy  Help to evaluate the treatment results  Follow-up
  • 28.
    Diagnostic Evaluation  CTScan  Extent of tumor  Neck node involvement  Skull base erosion  MRI – radiologic modality of choice  Determine if any intracranial extension of the tumour involves the brain parenchyma or the cavernous sinus  MRI > CT for displaying both superficial and deep nasopharyngeal soft tissue and for differentiating tumor from soft tissue.
  • 29.
  • 30.
  • 31.
  • 32.
    Diagnostic Evaluation  Positronemission tomography (PET) : - Useful in diagnosing recurrent /residual lesion following RT. -Useful to exclude distant metastasis before major salvage .  Chest x-ray: To identify lung metastasis  Abdominal ultrasound: To find liver metastasis.  Bone scan.
  • 33.
  • 34.
  • 35.
    Diagnostic Evaluation Laboratory evaluation CBC,  LFT’s  Special diagnostic tests (for types II & III)  IgA antibodies for viral capsid antigen (VCA)  IgG antibodies for early antigen (EA)  Antibody Dependent Cellular Cytotoxicity assay.
  • 36.
    Diagnostic Evaluation  Biopsy: first necessary investigation for NPC  Endoscopic biopsy : Ideally it shuold be carried out during the patient’s ist outpatient visit in suspected cases.  The most common sites are roof of nasopharynx and fossae of Rosenmuller.  FNA biopsy : should be done in suspicious neck lump. Histopathological Evaluation
  • 37.
    T.N.M. staging T1 =Tumour confined to the nasopharynx or extends to oropharynx and/or nasal cavity T2 = Tumour with parapharyngeal extension T3 = invasion of bony structures or P.N.S. T4 = intracranial, involvement of orbit, cranial nerves, infratemporal fossa, hypopharynx
  • 38.
    T.N.M. staging N0 =no evidence of regional lymph nodes N1 = unilateral N2 = bilateral (Both are above supraclavicular fossa & < 6 cm) N3 = > 6 cm or in supraclavicular foss N3a- greater than 6 cm in dimension N3b- extension to the supraclavicular fossa M0 = no evidence of distant metastasis M1 = distant metastasis present
  • 39.
    T.N.M. staging  StageI = T1 N0 M0  Stage II = T2 or N1 M0  Stage III = T3 or N2 M0  Stage IV = T4 or N3 or M1
  • 40.
  • 41.
    Treatment  The managementof NPC is unique for two reasons: 1-Tumor is in a relatively inaccessible location 2-Tumors is extremely radiosensitive
  • 42.
    Treatment Treatment Modalities  Radiotherapy(modality of choice)  Chemotherapy : combination with radiotherapy in advance disease  Surgery :To salvage local and regional failure
  • 43.
    Radiotherapy Modes of radiotherapy Teletherapy or External beam radiotherapy :Radiation beams projected to the target area through skin  Brachytherapy :uses radioactive material which are placed in close contact with tumor tissue . Interstitial: Radioactive source inserted into tumor tissue Intracavitary: Radioactive source placed inside catheter or moulds & inserted into nasopharynx
  • 44.
    Radiotherapy Modes of radiotherapy Intensity modulated radiation therapy (IMRT): recent development in delivery of radiotherapy where maximum dose can be delivered to the tumor but saving important normal structure  Stereotactic radiosurgery delivers radiation therapy precisely to the tumor using a machine called a gamma knife. This can be used to treat tumors that have invaded the base of the skull, or tumors that have recurred at the base of the brain or skull.
  • 45.
    primary treatment Radiotherapy  Externalbeam radiotherapy is most commonly delivered by opposed lateral fields to encompass the primary tumor and upper neck  Treatment field has to cover nasopharynx ,paraphryngeal space ,oropharynx ,skull base,sphenoid sinus ,posterior ethmoid ,posterior half of maxillary sinus  Bilateral Cervical nodal irradiation is mandatory even in clinically node-negative patients
  • 46.
  • 47.
    primary treatment  Radiotherapy 65-70 GY for primary  65-70 GY for positive L.N  50-60 GY for negative L.N  It should be delivered single fraction daily ,five per week without interruption .  Proper shielding of all critical structures as well as surrounding normal tissue is important.
  • 48.
    primary treatment Radiotherapy  Radiationboosts in the form of intracavitary brachytherapy for T1 to T2 lesions have been used to improve local control rates  Stereotactic radiosurgery boosts may also be given for T3 and T4 lesions.
  • 49.
    primary treatment Chemotherapy  Chemotherapyis believed to act as radiosensitizer.  It helps to reduce the chance of distant metastasis.  For locally advanced disease (stage III-IV ) chemotherapy in addition to radiotherapy appears to improve overall results.  Combination chemotherapy produces better responses  combination cisplatin/5-flurouracil is the most widely used  Indicates that concurrent chemoradiotherapy has a major role in advanced stage NPC
  • 50.
    primary treatment Complications chemotharpy Bone marrow suppression  Sensorineural hearing loss  Renal impairment  Hair loss  Weight loss  Nausea and vomiting
  • 51.
    primary treatment FOLLOW-UP PLAN: Close monitoring of the progress during and after treatment is necessary .  Follow-up endoscopy at 6–8 weeks and imaging at 10–12 weeks after completion of radiotherapy or chemoradiotherapy is recommended to document tumour responses.  malignancy detected after 10 weeks usually represents viable tumour and salvage treatment is indicated
  • 52.
    primary treatment FOLLOW-UP PLAN: Close monitoring of the progress during and after treatment is necessary .  The majority of relapses occur in first three years .  After primary treatment, patient should be seen :  Two-monthly for the first year  Three –monthly for 2nd and third year  Six –monthly thereafter.  Lifelong follow-up is needed as very late recurrence may also occur
  • 53.
    primary treatment  FOLLOW-UPPLAN:  The response of local disease is best followed up by repeated nasoendoscopy .  Post-treatment biopsy indicated if there is any residual swelling at the primary site .  Imaging is often needed to evaluate regional disease .
  • 54.
    Salvage treatment Treatment ofrecurrence  Recurrence at the primary site can be treated by surgery or re-irradiation.  Further dose of ERT may be considered.  Brachytherapy is preferred.  Cervical nodal recurrences are best treated by surgery .
  • 55.
    Salvage treatment surgery • Dueto deep location of nasopharynx, and anatomic proximity to critical structures, radical surgery is typically not used • Limited to  biopsy  Neck dissections for persistently enlarged lymph nodes  Nasopharyngectomy in persistent or recurrent disease
  • 56.
    Salvage treatment Nasopharyngectmy  Surgicalapproaches to the nasopharynx:  Anterior approaches  Inferior approaches  Lateral approaches
  • 57.
    Salvage treatment Anterior approaches:  Lateral rhinotomy  Transnasl transmaxillary  Midfacial degloving  Maxillary swing (most common approach )
  • 58.
    Salvage treatment Inferior approaches:  Transplatal :For localized tumour in the lower part of the posterior wall of the nasopharynx  Mandibular swing
  • 59.
     lateral infratemporalfossa approach: When the main tumour bulk is located in the paranasopharyngeal space close or lateral to internal carotid artery
  • 60.
    Salvage treatment  Surgicalsalvage for neck disease:  If a neck node persists in the absence of distant metastasis ,radical neck disection (RND)should be performed
  • 61.
    Prognosis  Approximate 5years survival rates for NPC
  • 62.
    Prognostic factors  TNM EBV  pathologic type  Old age  Cranial nerve palsy  Level and Fixity of nodes 
  • 63.
    Complications of Radiotherapy xerostomia  Oropharyngeal mucositis  Alopecia  Otitis media with effusion(OME)  Otitis externa  Rhinosinusitis  Trismus  Neck stiffness  Dysphagia  sensorineural deafness